Jean-christophe C. Thery

Rouen, FR 
Rouen, FR 

Overview

Jean-christophe Thery practices practicing medicine in Rouen, France.

His clinical expertise encompasses Breast Cancer, HER-2 Positive Breast Cancer, Choroid Plexus Carcinoma, and Cerebral Ventricle Cancer.

He is actively involved in clinical research, co-authoring 25 peer reviewed articles and participating in 5 clinical trials.

Gender

Male

Locations

Rouen, France
Other Locations
Lille, France
Caen, 14000, France
Paris, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Use of Cognitive Stimulation Software for Patients Over the Age of 70 Followed for Breast Cancer: COG-TAB-AGE Feasibility Study
Use of Cognitive Stimulation Software for Patients Over the Age of 70 Followed for Breast Cancer: COG-TAB-AGE Feasibility Study
Enrollment Status: Completed
Publish Date: July 02, 2026
Intervention Type: Other
Study Phase: Not Applicable
Efficacy of Regorafenib as Maintenance Therapy in Non-adipocytic Soft Tissue Sarcoma Having Received First-line Doxorubicin-based Chemotherapy
Efficacy of Regorafenib as Maintenance Therapy in Non-adipocytic Soft Tissue Sarcoma Having Received First-line Doxorubicin-based Chemotherapy
Enrollment Status: Completed
Publish Date: March 18, 2026
Intervention Type: Drug
Study Drug: Regorafenib
Study Phase: Phase 2
PERSONALIZED MEDICINE GROUP / UCBG UC-0105/1304: SAFIR02_Breast - Evaluation of the Efficacy of High Throughput Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer
PERSONALIZED MEDICINE GROUP / UCBG UC-0105/1304: SAFIR02_Breast - Evaluation of the Efficacy of High Throughput Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 15, 2025
Intervention Type: Drug
Study Drugs: AZD2014, AZD4547, AZD5363, AZD8931, Selumetinib, Vandetanib, Bicalutamide, Olaparib, Anthracyclines, Taxanes, Cyclophosphamide, DNA Intercalators, Methotrexate, Vinca Alkaloids, Platinum Based Chemotherapies, Bevacizumab, Mitomycin C, Eribulin, MEDI4736
Study Phase: Phase 2
A Phase II Randomized Trial Comparing Alpelisib and Fulvestrant Versus Chemotherapy as Maintenance Therapy in Patients With PIK3CA Mutated Advanced Breast Cancer
A Phase II Randomized Trial Comparing Alpelisib and Fulvestrant Versus Chemotherapy as Maintenance Therapy in Patients With PIK3CA Mutated Advanced Breast Cancer
Enrollment Status: Terminated
Publish Date: November 28, 2022
Intervention Type: Drug
Study Drugs: Alpelisib, Chemotherapy
Study Phase: Phase 2
A Randomized, Double-blind, Placebo-controlled Phase III Study, to Evaluate the Efficacy of Afatinib (BIBW2992) in Maintenance Therapy After Post- Operative Radio-chemotherapy in Squamous-cell Carcinoma of the Head and Neck: GORTEC 2010-02
A Randomized, Double-blind, Placebo-controlled Phase III Study, to Evaluate the Efficacy of Afatinib (BIBW2992) in Maintenance Therapy After Post- Operative Radio-chemotherapy in Squamous-cell Carcinoma of the Head and Neck: GORTEC 2010-02
Enrollment Status: Completed
Publish Date: June 01, 2021
Intervention Type: Drug
Study Drug: Afatinib
Study Phase: Phase 3
View 4 Less Clinical Trials

25 Total Publications

Optimising rare tumour risk syndromes care: clinical insights and the PREVENTABLE socioeconomic framework.
Optimising rare tumour risk syndromes care: clinical insights and the PREVENTABLE socioeconomic framework.
Journal: European journal of human genetics : EJHG
Published: June 23, 2025

Frequently Asked Questions about Jean-christophe C. Thery

Is Jean-christophe C. Thery a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Jean-christophe C. Thery is classified as an Experienced expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Jean-christophe C. Thery participate in research or clinical trials?

Yes. Jean-christophe C. Thery has published 25 articles and abstracts on conditions like Breast Cancer. You can view a list of Jean-christophe C. Thery's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Thery's expertise for a condition
ConditionClose
        View All 8 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile